Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.
Jordan Clark
Advertisement
Articles by Jordan Clark
Advertisement
Latest Updated Articles
Retesting for FLT3 Mutation Status in AMLJuly 9th 2019
Advertisement
Advertisement
Trending on OncLive
1
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
4
QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML
5